⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Disease Modifying Therapy Utilization in Pediatric Multiple Sclerosis: A Multi-center Retrospective Study (P1-6.008)

Amara Miller Heather E. Held Thomas A. DeCesare Frederick Bassal Vaishnavi Vaidyanathan Jonathan D. Santoro

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate trends in DMT use in individuals with POMS and determine if there were demographic factors that influence utilization.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Miller et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c7b https://doi.org/10.1212/wnl.0000000000206667

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Disease-modifying therapy uptake in a pediatric-onset multiple sclerosis population, British Columbia, Canadacohort · 2026
2Effectiveness and Safety of High-efficacy Disease-modifying Therapy in Pediatric Multiple Sclerosis: A Retrospective Analysis at a Single Center (P4-6.017)2024 · 1 citations
3Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis2024 · 1 citations
4Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis2024 · 11 citations
5Real-world use of disease-modifying therapy in persons with multiple sclerosis aged 55 and over.2025 · 2 citations